Abstract:INTRODUCTION: Factor VIII has been shown to play an important role in cirrhotic patients with hypercoagulable phenotype. However, the role of factor VIII in portal vein thrombosis (PVT) among cirrhosis has not been well studied. We aimed to evaluate the association between increased level of factor VIII and PVT occurrence, as well as the extent of thrombosis in cirrhotic patients with clinical portal hypertension. METHODS: All cirrhotic patients aged 18–75 with confirmed gastroesophageal varices (GEV) seen at a regional referral center between January 1, 2018 and December 31, 2019 were enrolled. Patients with a history of liver transplantation, TIPS, malignant tumor, or cavernous transformation of the portal vein were excluded. A total of 424 patients were included and divided into PVT group (n = 96) vs non-PVT group (n = 328) based on the presence of PVT on computed tomography angiography report. RESULTS: The mean age of all included patients with cirrhosis and GEV was 57.0 ± 10.8 years, 61.1% (259) were male, 22.6% (96) with PVT, 20.5% (87) with a history of splenectomy. Factor VIII level was significantly higher in the PVT group compared with the non-PVT group (181.5 ± 65.9% vs 160.5 ± 53.4%, P = 0.005). PVT group was also noted to have significantly higher Child-Pugh grade, MELD score, splenectomy rate, prothrombin time, and significantly lower hemoglobin and albumin level compared with non-PVT group (Table 1). There were 71 cases with thrombosis in the main trunk, 26 in the left branch, 49 in the right branch, 28 in the superior mesenteric vein, and 24 in the splenic vein. Elevated factor VIII level was found to associate with increased occurrence of thrombosis in the main trunk (HR 1.007, 95% CI 1.003–1.011, P = 0.001), left branch (HR 1.011, 1.001–1.017, P = 0.001), right branch (HR 1.009, 1.004–1.014, P < 0.001), and superior mesenteric vein (HR 1.009, 1.003–1.015, P = 0.003); however, it had no effect on the occurrence of splenic vein thrombosis (HR 0.999, 0.992–1.007, P = 0.887). The level of factor VIII was positively correlated with the number of sites (0–4; main trunk, left branch, right branch, superior mesenteric vein) involved with thrombosis. (Figure 1) CONCLUSION: Elevated level of factor VIII was associated with occurrence of PVT and positively correlated with the number of sites involved with thrombosis in the portal system. Further studies are required to investigate the underlying mechanism of such correlations.Table 1Figure 1.: The level of Factor VIII (FVIII%, Median, interquartile) and the number of sites with thrombosis in portal system.

Platelet Activation is Upregulated in Cirrhotic Patients with Portal Vein Thrombosis.

A Single Hospital Study on Portal Vein Thrombosis in Cirrhotic Patients - Clinical Characteristics & Risk Factors.

Platelet-derived TGF-β1 is Related to Portal Vein Thrombosis in Cirrhosis by Promoting Hypercoagulability and Endothelial Dysfunction

Novel insights into the development of portal vein thrombosis in cirrhosis patients

Platelet Function Decreases with Increasing Severity of Liver Cirrhosis and Portal Hypertension-A Prospective Study

Predicting the risk of variceal rehemorrhage in cirrhotic patients with portal vein thrombosis: A two-center retrospective study

Clinical analysis of portal vein thrombosis in patients with liver cirrhosis

Increased Portal Vein Diameter is Predictive of Portal Vein Thrombosis Development in Patients with Liver Cirrhosis

Risk factors of portal venous thrombosis development in patients with portal hypertension

[New targets for the prevention and treatment of cirrhotic portal vein thrombosis]

Portal Vein Thrombosis Can Aggravate Esophageal Variceal Bleeding After Endoscopic Variceal Ligation

Analysis of the Etiology of Portal Vein Thrombosis in Liver Cirrhosis Patients

Occlusive Portal Vein Thrombosis As A New Marker of Decompensated Cirrhosis

Platelet Activation Status in the Diagnosis and Postoperative Prognosis of Hepatocellular Carcinoma.

Measurement and Clinical Significance of Peripheral Blood Vascular Endothelial Growth Factor in Patients with Liver Cirrhosis and Portal Vein Thrombosis

Risk factors for non-neoplastic portal vein thrombosis in patients with liver cirrhosis

Safety, Efficacy and Prognosis of Anticoagulant Therapy for Portal Vein Thrombosis in Cirrhosis: a Retrospective Cohort Study

Clinical characteristics and predictors of benign portal vein thrombosis in patients with liver cirrhosis: A retrospective single-center study

S0981 Elevated Factor VIII Level is Associated with the Occurrence and Extent of Portal Vein Thrombosis in Cirrhosis

Prevalence and Clinical Significance of Portal Vein Thrombosis in Cirrhotic Patients with Acute Decompensation

Expression of Platelet-Derived Endothelial Cell Growth Factor and Vascular Endothelial Growth Factor in Hepatocellular Carcinoma and Portal Vein Tumor Thrombus